Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 5 | 5 |
1.1 List of Tables | 8 | 1 |
1.2 List of Figures | 8 | 2 |
2 Introduction | 10 | 16 |
2.1 Disease Introduction | 11 | 1 |
2.2 Epidemiology | 11 | 1 |
2.3 Symptoms | 12 | 2 |
2.4 Etiology and Pathophysiology | 14 | 1 |
2.4.1 Pathophysiology | 14 | 1 |
2.5 Diagnosis | 15 | 2 |
2.6 Disease Stages | 17 | 3 |
2.7 Prognosis | 20 | 1 |
2.8 Treatment Options | 21 | 1 |
2.8.1 Treatment Algorithm | 21 | 1 |
2.8.2 Pharmacological Treatments | 22 | 1 |
2.8.2.1 Bisphosphonates | 23 | 1 |
2.8.2.2 Dual-Action Non-Bisphosphonates | 23 | 1 |
2.8.2.3 Selective Estrogen Receptor Modulators | 23 | 1 |
2.8.2.4 Receptor Activator of Nuclear Factor Kappa-B Ligand Inhibitor | 23 | 1 |
2.8.2.5 Parathyroid Hormone | 24 | 1 |
2.8.2.6 Calcitonins | 24 | 1 |
2.8.3 Non-Pharmacological Treatments | 24 | 1 |
2.8.4 Exercise | 24 | 1 |
2.8.5 Dietary Interventions | 24 | 2 |
3 Marketed Products | 26 | 16 |
3.1 Overview | 26 | 1 |
3.2 46TBisphosphonates | 26 | 1 |
3.2.1 Risedronate Warner Chilcott | 26 | 2 |
3.2.2 Alendronate Merck &Co | 28 | 1 |
3.2.3 Boniva (ibandronate) Roche | 29 | 1 |
3.2.4 Zoledronic Acid Novartis | 30 | 1 |
3.2.5 Recalbon/Bonoteo (minodronate) Ono and Astellas Pharma | 31 | 1 |
3.2.6 Etidronate Procter &Gamble and Sumitomo Pharmaceuticals | 32 | 1 |
3.3 Dual-Acting Non-Bisphosphonates | 33 | 1 |
3.3.1 Strontium Ranelate Servier | 33 | 1 |
3.4 Selective Estrogen Receptor Modulators | 34 | 1 |
3.4.1 Evista (raloxifene) Eli Lilly | 34 | 1 |
3.4.2 Viviant (bazedoxifene) Ligand and Pfizer | 35 | 1 |
3.5 Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Inhibitor | 36 | 1 |
3.5.1 Prolia (denosumab) Amgen | 36 | 1 |
3.6 Calcitonins | 37 | 1 |
3.6.1 Calcitonin-salmon | 37 | 1 |
3.7 Parathyroid Hormone | 38 | 1 |
3.7.1 Forteo (teriparatide) Eli Lilly | 38 | 1 |
3.8 Comparative Efficacy and Safety of Marketed Products | 39 | 3 |
4 Pipeline Analysis | 42 | 19 |
4.1 Overview | 42 | 1 |
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type | 43 | 2 |
4.3 Pipeline by Molecular Target | 45 | 3 |
4.4 Promising Pipeline Candidates | 48 | 1 |
4.4.1 Romosozumab (AMG-785) Amgen | 48 | 3 |
4.4.2 Abaloparatide-SC (BA-058-SC) Radius Health | 51 | 3 |
4.4.3 Odanacatib (MK-0822 ) Merck &Co | 54 | 2 |
4.4.4 Uni-PTH Uni-Bio Science | 56 | 2 |
4.5 Comparative Efficacy and Safety of Pipeline Products | 58 | 1 |
4.6 Product Competitiveness Framework | 59 | 2 |
5 Clinical Trial Analysis | 61 | 12 |
5.1 Failure Rate | 61 | 1 |
5.1.1 Overall Failure Rate | 61 | 2 |
5.1.2 Failure Rate by Phase and Molecule Type | 63 | 1 |
5.1.3 Failure Rate by Phase and Molecular Target | 63 | 1 |
5.2 Clinical Trial Duration | 64 | 1 |
5.2.1 Clinical Trial Duration by Molecule Type | 64 | 2 |
5.2.2 Clinical Trial Duration by Molecular Target | 66 | 1 |
5.3 Clinical Trial Size | 67 | 1 |
5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development | 67 | 2 |
5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development | 69 | 2 |
5.4 Competitive Clinical Trials Metrics Analysis | 71 | 2 |
6 Multi-Scenario Forecast | 73 | 19 |
6.1 Geographical Markets | 73 | 1 |
6.2 Asia-Pacific Market | 74 | 1 |
6.3 India | 75 | 1 |
6.3.1 Treatment Usage Patterns | 75 | 2 |
6.3.2 Annual Cost of Therapy | 77 | 1 |
6.3.3 Market Size | 78 | 1 |
6.4 China | 79 | 1 |
6.4.1 Treatment Usage Patterns | 79 | 1 |
6.4.2 Annual Cost of Therapy | 80 | 1 |
6.4.3 Market Size | 81 | 1 |
6.5 Australia | 82 | 1 |
6.5.1 Treatment Usage Patterns | 82 | 1 |
6.5.2 Annual Cost of Therapy | 83 | 2 |
6.5.3 Market Size | 85 | 1 |
6.6 South Korea | 86 | 1 |
6.6.1 Treatment Usage Patterns | 86 | 1 |
6.6.2 Annual Cost of Therapy | 87 | 1 |
6.6.3 Market Size | 88 | 1 |
6.7 Japan | 89 | 1 |
6.7.1 Treatment Usage Patterns | 89 | 1 |
6.7.2 Annual Cost of Therapy | 89 | 1 |
6.7.3 Market Size | 90 | 2 |
7 Drivers and Barriers | 92 | 3 |
7.1 Drivers | 92 | 1 |
7.1.1 Rising Prevalence | 92 | 1 |
7.1.2 Increasing Health Insurance Coverage for Aged Population | 92 | 1 |
7.1.3 Increasing Public and Policymaker Awareness | 92 | 1 |
7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm | 93 | 1 |
7.2 Barriers | 93 | 1 |
7.2.1 Impending Patent Cliffs and Generic Erosion | 93 | 1 |
7.2.2 Low Diagnosis and Treatment Rates | 93 | 1 |
7.2.3 Non-Availability or Lack of Benefits for Combination Anabolic and Antiresorptive Therapies | 93 | 1 |
7.2.4 Competition from Traditional Medicines | 94 | 1 |
8 Deals and Strategic Consolidations | 95 | 11 |
8.1 Licensing Deals | 95 | 1 |
8.1.1 Deals by Region and Value | 95 | 1 |
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value | 96 | 1 |
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target | 96 | 3 |
8.1.4 Key Licensing Deals | 99 | 1 |
8.1.4.1 Licensing Agreement between Sermonix and Ligand Pharmaceuticals | 99 | 1 |
8.1.4.2 Licensing Agreement between Galapagos and Eli Lilly | 99 | 1 |
8.1.4.3 Licensing Agreement between Dong Wha Pharma and Procter &Gamble | 100 | 1 |
8.1.4.4 Licensing Agreement between Nastech Pharma and Procter &Gamble | 100 | 1 |
8.1.4.5 Licensing Agreement between Daiichi Sankyo and Amgen | 100 | 1 |
8.2 Co-Development Deals | 101 | 1 |
8.2.1 Deals by Region and Value | 101 | 1 |
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value | 102 | 1 |
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target | 103 | 1 |
8.2.4 Key Co-Development Deals | 104 | 1 |
8.2.4.1 Co-Development Agreement between Unigene Laboratories and GlaxoSmithKline | 104 | 1 |
8.2.4.2 Co-Development Agreement between Radius Health and 3M Drug Delivery Systems | 104 | 1 |
8.2.4.3 Co-Development Agreement between MorphoSys and Galapagos | 104 | 1 |
8.2.4.4 Co-Development Agreement between Interleukin and Access Business Group | 104 | 1 |
8.2.4.5 Co-Development Agreement between Chugai Pharma and Taisho Pharma | 105 | 1 |
9 Appendix | 106 | 26 |
9.1 All Pipeline Drugs by Stage of Development | 106 | 6 |
9.1.1 Discovery | 106 | 2 |
9.1.2 Preclinical | 108 | 2 |
9.1.3 Investigational New Drug/ Clinical Trial Authorization-Filed | 110 | 1 |
9.1.4 Phase I | 110 | 1 |
9.1.5 Phase II | 111 | 1 |
9.1.6 Phase III | 111 | 1 |
9.1.7 Pre-registration | 111 | 1 |
9.2 Market Forecasts to 2021 | 112 | 3 |
9.2.1 Asia-Pacific | 112 | 1 |
9.2.2 India | 112 | 1 |
9.2.3 China | 113 | 1 |
9.2.4 Australia | 113 | 1 |
9.2.5 South Korea | 114 | 1 |
9.2.6 Japan | 114 | 1 |
9.3 Bibliography | 115 | 11 |
9.4 Abbreviations | 126 | 1 |
9.5 Research Methodology | 127 | 5 |
9.5.1 Secondary Research | 128 | 1 |
9.5.2 Marketed Product Profiles | 128 | 1 |
9.5.3 Late-Stage Pipeline Candidates | 128 | 1 |
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products | 129 | 1 |
9.5.5 Product Competitiveness Framework | 129 | 1 |
9.5.6 Pipeline Analysis | 129 | 1 |
9.5.6.1 Overall Pipeline | 129 | 1 |
9.5.6.2 Clinical Trials | 129 | 1 |
9.5.6.3 Failure Rate | 129 | 1 |
9.5.6.4 Clinical Trial Size | 130 | 1 |
9.5.6.5 Clinical Trial Duration | 130 | 1 |
9.5.6.6 Clinical Trial Endpoint Analysis | 130 | 1 |
9.5.7 Forecasting Model | 130 | 1 |
9.5.8 Deals Data Analysis | 131 | 1 |
9.6 Contact Us | 131 | 1 |
9.7 Disclaimer | 131 | 1 |